These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 4431859)

  • 1. Proceedings: Mechanism of antidepressant efficacy of monoamine oxidase inhibitors: inhibition of monoamine oxidase or of catecholamine reuptake.
    Snyder SH
    Psychopharmacol Bull; 1974 Oct; 10(4):16. PubMed ID: 4431859
    [No Abstract]   [Full Text] [Related]  

  • 2. [Data on the biochemical mechanism of action of antidepressive psychopharmacologic agents].
    Baconcini C; Muzio M
    Sist Nerv; 1971; 23(7):25-35. PubMed ID: 4360412
    [No Abstract]   [Full Text] [Related]  

  • 3. Proceedings: The "pharmacological bridge": a view from the clinical shores.
    Sack R; Goodwin FK
    Psychopharmacol Bull; 1974 Oct; 10(4):52-3. PubMed ID: 4431876
    [No Abstract]   [Full Text] [Related]  

  • 4. [A behavioral and neurochemical study on the mechanism of the anxiolytic effect of monoamine oxidase inhibitors].
    Maki Y
    Hokkaido Igaku Zasshi; 2001 May; 76(3):133-42. PubMed ID: 11481866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile.
    Caille D; Bergis OE; Fankhauser C; Gardes A; Adam R; Charieras T; Grosset A; Rovei V; Jarreau FX
    J Pharmacol Exp Ther; 1996 Apr; 277(1):265-77. PubMed ID: 8613929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of catecholamine uptake inhibition in the reversal of guanethidine blockade of adrenergic neurons.
    Lee CH; Strosberg AM; Warren LA
    Res Commun Chem Pathol Pharmacol; 1980 Oct; 30(1):3-14. PubMed ID: 7433767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
    Volz HP; Gleiter CH; Möller HJ
    Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors.
    Kennedy SH
    J Psychiatry Neurosci; 1997 Mar; 22(2):127-31. PubMed ID: 9074307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neurochemical and behavioral study on the mechanism of the antidepressant and anxiolytic effect of co-administration of lithium and monoamine oxidase inhibitors].
    Kitaichi Y
    Hokkaido Igaku Zasshi; 2004 Jan; 79(1):93-101. PubMed ID: 14978979
    [No Abstract]   [Full Text] [Related]  

  • 10. 3. Interaction of psychotropic drugs with agents employed in clinical anesthesia.
    Schmidt KF; Roth RH
    Clin Anesth; 1967; 3():59-86. PubMed ID: 4296506
    [No Abstract]   [Full Text] [Related]  

  • 11. Proceedings: Enhanced avoidance in poor performers as a model for evaluating antidepressant agents.
    Rech RH
    Psychopharmacol Bull; 1974 Oct; 10(4):18-9. PubMed ID: 4431860
    [No Abstract]   [Full Text] [Related]  

  • 12. Some aspects of the mechanism of action of various stimulant amphetamine analogues.
    Scheel-Krüger J
    Psychiatr Neurol Neurochir; 1972; 75(3):179-92. PubMed ID: 4402652
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effect of monoamine oxidase inhibitors on the content of catecholamines in different parts of the brain in cats].
    Vysotskaia NB; Kaverina NV; Mirzoian RS; Rozonov IuB
    Farmakol Toksikol; 1967; 30(3):289-92. PubMed ID: 5597732
    [No Abstract]   [Full Text] [Related]  

  • 14. Tranylcypromine: new perspectives on an "old" drug.
    Frieling H; Bleich S
    Eur Arch Psychiatry Clin Neurosci; 2006 Aug; 256(5):268-73. PubMed ID: 16927039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biochemical action mechanisms and pharmacokinetics of psychoactive drugs].
    Matussek N; Greil W
    Arzneimittelforschung; 1975 Jul; 25(7a):1178-84. PubMed ID: 1101905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic response of rats to stress after inhibition of catecholamine-degrading enzymes.
    Kvetnanský R; Vigas M; Németh S; Mikulaj L
    Physiol Bohemoslov; 1967; 16(4):373-8. PubMed ID: 4228116
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibitory effects of type A and type B monoamine oxidase inhibitors on synaptosomal accumulation of [3H]dopamine: a reflection of antidepressant potency.
    Azzaro AJ; Demarest KT
    Biochem Pharmacol; 1982 Jun; 31(12):2195-7. PubMed ID: 7115440
    [No Abstract]   [Full Text] [Related]  

  • 18. Monoamine oxidase inhibitors and neuroprotection: a review.
    Al-Nuaimi SK; Mackenzie EM; Baker GB
    Am J Ther; 2012 Nov; 19(6):436-48. PubMed ID: 22960850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Apropos of the mechanism of action of monoamine oxidase-inhibitors on the coronary circulation].
    Mirzoian RS
    Farmakol Toksikol; 1965; 28(1):51-5. PubMed ID: 5845043
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of five clinically used inhibitors of monoamine oxidase using the fluorescence microscopy method.
    Bartonícek V
    Med Pharmacol Exp Int J Exp Med; 1967; 16(2):142-6. PubMed ID: 5298397
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.